Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donepezil + roflumilast
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of donepezil, a cholinesterase inhibitor, and roflumilast, a phosphodiesterase-4 (PDE4) inhibitor. This combination is being investigated for its potential to enhance cognitive function and reverse cognitive deficits, particularly in Alzheimer's disease. Donepezil works by inhibiting the acetylcholinesterase enzyme, thereby increasing acetylcholine levels in the brain, while roflumilast prevents the breakdown of cyclic adenosine monophosphate (cAMP), affecting cell signaling and protein phosphorylation. Studies suggest that combining sub-efficacious doses of roflumilast and donepezil may be fully effective in improving spatial memory.
02
Targets
AcetylcholinesterasePDE4 (Phosphodiesterase 4A1)
Beyond the preview
Go deeper on donepezil + roflumilast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donepezil + roflumilast.